Stewart,
It does hurt watching the slow attrition in PPS; I've got to agree with your analysis. I'm holding and actually got more yesterday @ $1.10 for my retirement account. Unfortunatley, I think you got in a little later than me; but I believe if that BSX news hits there could be a major gap we could miss by being on the sidelines. BSX has all of Wall Streets attention with their Taxus stent. If Biophan gets another joint-release with BSX I believe there will be a flood of new investors trying to get in. The last filing indicated there were only 360 shareholders of record, that's the least number I've seen in my days of reviewing filings (which is limited). BSX is only one of the irons in the fire too. There's also statements in those filing indicating Biophan has turned down an offer from one of the major pacemaker manufacturers to seek more favorable terms. Seams like they might be on the verge of something there too? That's not to mention all the other statements indicating less progressed conversations with prosthetic device manufacturers, photonic for neurological disorders, coatings for contrast agents, etc..
It's a good risk/reward situation IMO. I just hope the tides turn soon here.
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854